CALR and essential thrombocythemia: The JAK2 V617F mutation was found in 73% (30/41) of the ET patients, with a median (range) allele burden of 22% (0.13–49.7%) A CALR mutation was found in 10% (4/41) of the ET patients, and none of the group was MPL positive.